Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia.

Bojang, Kalifa; Milligan, Paul; Pinder, Margaret; Doherty, Tom; Leach, Amanda; Ofori-Anyinam, Opokua; Lievens, Marc; Kester, Kent; Schaecher, Kurt; Ballou, W Ripley; +1 more... Cohen, Joe; (2009) Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. Human vaccines, 5 (4). pp. 242-247. ISSN 1554-8600 DOI: https://doi.org/10.4161/hv.5.4.7050

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.4161/hv.5.4.7050

Abstract

Share

Download

Full text not available from this repository.

Downloads

View details

Metrics & Citations


Google Scholar